265 related articles for article (PubMed ID: 3875779)
1. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK
Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
3. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
4. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Perez V; Unzeta M
Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
[TBL] [Abstract][Full Text] [Related]
5. Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP.
Fuller RW; Hemrick-Luecke SK
J Pharm Pharmacol; 1987 Aug; 39(8):667-9. PubMed ID: 2888865
[TBL] [Abstract][Full Text] [Related]
6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
7. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
Fuller RW; Wong CJ; Hemrick-Luecke SK
Life Sci; 1986 Feb; 38(5):409-12. PubMed ID: 3945167
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fuller RW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice.
Fuller RW; Hemrick-Luecke SK
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):687-90. PubMed ID: 3878976
[TBL] [Abstract][Full Text] [Related]
10. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
[TBL] [Abstract][Full Text] [Related]
11. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen JN; Sobotka TJ; Weise VK; Markey SP
J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
[TBL] [Abstract][Full Text] [Related]
12. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK; Perry KW
J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
Finnegan KT; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
[TBL] [Abstract][Full Text] [Related]
14. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice.
Araki T; Kumagai T; Matsubara M; Ido T; Imai Y; Itoyama Y
Metab Brain Dis; 2000 Sep; 15(3):193-201. PubMed ID: 11206588
[TBL] [Abstract][Full Text] [Related]
16. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Youngster SK; Sonsalla PK; Heikkila RE
J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
[TBL] [Abstract][Full Text] [Related]
18. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study.
Colzi A; d'Agostini F; Kettler R; Borroni E; Da Prada M
J Neural Transm Suppl; 1990; 32():79-84. PubMed ID: 2089114
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
